Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.

Herasimtschuk A, Downey J, Nelson M, Moyle G, Mandalia S, Sikut R, Adojaan M, Stanescu I, Gotch F, Imami N.

Vaccine. 2014 Dec 5;32(51):7005-13. doi: 10.1016/j.vaccine.2014.09.072. Epub 2014 Oct 22.

PMID:
25454870
2.

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors.

Barber TJ, Moyle G, Hill A, Singh GJ, Boffito M, Nelson M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19827. doi: 10.7448/IAS.17.4.19827. eCollection 2014.

3.

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor.

Fisher M, McDonald C, Moyle G, Martorell C, Ramgopal M, Laplante F, Curley J, Graham H, Tran-Muchowski C, Liu Y, Rhee M, Szwarcberg J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19824. doi: 10.7448/IAS.17.4.19824. eCollection 2014.

4.

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor.

Barber T, Hill A, Singh GJ, Boffito M, Nelson M, Moyle G.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19562. doi: 10.7448/IAS.17.4.19562. eCollection 2014.

5.

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study.

Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group.

J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3.

6.

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.

Singh GJ, Jackson A, D'Avolio A, Else L, De Nicolò A, Bonora S, Di Perri G, Khoo S, Back D, Moyle G, Boffito M.

AIDS. 2014 Aug 24;28(13):1993-5. doi: 10.1097/QAD.0000000000000356. No abstract available.

PMID:
25259708
7.

Virological efficacy of abacavir: systematic review and meta-analysis.

Cruciani M, Mengoli C, Malena M, Serpelloni G, Parisi SG, Moyle G, Bosco O.

J Antimicrob Chemother. 2014 Dec;69(12):3169-80. doi: 10.1093/jac/dku279. Epub 2014 Jul 28.

PMID:
25074854
8.

Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy.

Moyle G, Hardy H, Uy J, Ray N, Jimenez-Exposito MJ, McGrath D, DeJesus E.

Antivir Ther. 2014;19(7):693-9. doi: 10.3851/IMP2778. Epub 2014 Apr 16.

PMID:
24739445
9.

Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.

Jackson A, D'Avolio A, Moyle G, Bonora S, Di Perri G, Else L, Simiele M, Singh GJ, Back D, Boffito M.

J Antimicrob Chemother. 2014 Jul;69(7):1911-5. doi: 10.1093/jac/dku060. Epub 2014 Mar 6.

PMID:
24610312
10.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

PMID:
24525316
11.

Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N, Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M.

Antimicrob Agents Chemother. 2013 Aug;57(8):3640-4. doi: 10.1128/AAC.00357-13. Epub 2013 May 20.

12.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK.

J Infect Dis. 2013 Jul;208(1):32-9. doi: 10.1093/infdis/jit122. Epub 2013 Mar 26.

13.

NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials.

Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, Orkin C, Fisher M, Vanhove GF, Tobias JK.

AIDS Res Ther. 2013 Jan 28;10(1):5. doi: 10.1186/1742-6405-10-5.

14.

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):275-81. doi: 10.1097/QAI.0b013e3182829bd0.

PMID:
23274933
15.

Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach.

Peters B, Post F, Wierzbicki AS, Phillips A, Power L, Das S, Johnson M, Moyle G, Hughes L, Wilkins E, McCloskey E, Compston J, Di Angelantonio E.

HIV Med. 2013 Jan;14 Suppl 1:1-11. doi: 10.1111/j.1468-1293.2012.01055.x. Review.

PMID:
23121515
16.

CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.

Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S, Imami N.

Mol Med. 2012 Oct 24;18:1240-8. doi: 10.2119/molmed.2012.00206.

17.

Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.

Vrouenraets SM, Wit FW, Garcia EF, Huber M, Brinkman K, Moyle G, Domingo P, Tarr PE, Podzamczer D, Ristola M, Gatell JM, Livrozet JM, Furrer H, Reiss P; PREPARE Study Group.

HIV Clin Trials. 2012 Mar-Apr;13(2):103-10. doi: 10.1310/hct1302-103.

PMID:
22510357
18.

Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, McGrath D, Farajallah A, Moyle G.

AIDS Patient Care STDS. 2012 May;26(5):259-64. doi: 10.1089/apc.2011.0092. Epub 2012 Mar 9.

19.

Room for manoeuvre when prescribing statins to dyslipidaemic patients on antiretroviral therapy.

Myers J, Rayment M, Sonecha S, Moyle G, Boffito M.

HIV Med. 2012 Mar;13(3):190-2. doi: 10.1111/j.1468-1293.2011.00957.x. No abstract available.

PMID:
22296166
20.

Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J, Gedela K, Abongomera G, Gazzard B, Boffito M.

Antivir Ther. 2012;17(1):19-24. doi: 10.3851/IMP1910.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk